Haemochromatosis: Iron Overload, Tests and Treatment

Patient guide · Sources checked 8 October 2026

Haemochromatosis can raise questions about blood tests, inherited risk and ongoing care. This guide explains the language used in appointments and how to prepare for decisions with your healthcare team. It is general education, not a diagnosis or a personal treatment plan.

What haemochromatosis means

Haemochromatosis is an inherited disorder of iron regulation that can allow more iron to enter the body than it needs. You may also see the American spelling, hemochromatosis. Specialists increasingly reserve this name for particular genetic disorders, while using iron overload for the wider group of conditions in which excess iron accumulates. The distinction matters because the reason for overload helps determine the investigation and treatment. ^[1]

Iron itself is essential. It helps form haemoglobin, the protein that carries oxygen in red blood cells, and myoglobin, which supports oxygen supply in muscles. Iron also contributes to growth, development and hormone production. The aim of care is therefore to manage an excess while preserving the iron needed for normal functions. Thinking of all iron as harmful misses why treatment needs careful supervision. ^[2]

In many forms of haemochromatosis, the problem involves hepcidin, a hormone made by the liver that helps control iron entering the circulation. Too little effective hepcidin signalling can leave the normal restraint on iron absorption inadequate. This explains why the condition can develop with an ordinary diet and why it is misleading to describe it simply as eating too much iron. ^[1]

After iron is absorbed from the gut, transferrin carries it through the bloodstream. Some is delivered to the bone marrow for making red blood cells, and some is stored in the liver. When absorption repeatedly exceeds the body’s needs, stored iron can gradually accumulate. In the common adult form, this usually develops over time rather than after a particular meal. The liver is central both to storage and to regulation, which helps explain why liver assessment has such an important place in the diagnostic pathway. ^[18]

Hereditary haemochromatosis and other iron overload

Iron overload can also develop in association with other illnesses or their treatment. Repeated blood transfusions, for example, can supply additional iron to someone who needs transfusions for anaemia. Some liver disorders also affect iron handling. These situations may be labelled secondary iron overload, and sometimes secondary haemochromatosis in general health information. Management includes considering the underlying condition, rather than automatically applying a hereditary haemochromatosis treatment plan. ^[3]

The most familiar inherited form involves the HFE gene. Other genes associated with hereditary iron disorders include HJV, HAMP, TFR2 and SLC40A1. Their effects and inheritance patterns differ; some rare forms appear earlier in life. HFE-related disease is usually described as autosomal recessive, involving changes in both gene copies. Some SLC40A1-related disorders follow a different pattern. A generic family diagram cannot explain every person’s result. ^[4]

In a recessive condition, a parent can carry a relevant variant without having the condition themselves. A family can therefore encounter a diagnosis without a previously recognised pattern of illness in every generation. This is one reason that understanding the particular gene result is more useful than trying to infer inheritance from who in the family looks or feels healthy. ^[4]

Some inherited blood disorders can also cause iron loading without being haemochromatosis. In these disorders, ineffective production of red blood cells can alter the signals controlling absorption. This is a different starting problem from HFE-related haemochromatosis, where the primary defect is in iron regulation. It also explains why an inherited condition, anaemia and excess body iron can occur together. “Inherited” and “iron overload” are therefore not sufficient, on their own, to identify the mechanism or choose blood removal as treatment. ^[19]

A genetic result is only one part of the picture

A genotype describes the gene variants a person has. Clinical disease describes what is happening to their health. GeneReviews distinguishes people with HFE-related organ injury, people with biochemical evidence of iron accumulation without such injury, and people whose genetic predisposition has not produced iron overload. This variable expression is called incomplete penetrance. Having two HFE C282Y variants does not, by itself, establish that organs are damaged or predict an identical course for every person. ^[5]

People who share a genotype can have different clinical findings. Age, sex and other health or environmental factors influence the picture. The HFE C282Y pattern is particularly associated with northern European ancestry. Genetic information needs interpretation alongside iron measurements and clinical assessment. ^[5]

Genetic reports often use homozygous for two copies of the same variant and heterozygous for a variant in one copy. Compound heterozygous refers to two different variants, one in each copy of the gene. These words describe a genetic pattern, not a severity score. C282Y may also appear in the longer form p.Cys282Tyr, while H63D may appear as p.His63Asp. A report should connect its finding to the reason for testing and the clinical information. Finding a susceptibility variant during family testing is different from explaining established iron overload in someone already being investigated. ^[20]

Consumer genetic reports have additional limits. Companies do not necessarily test the same variants, and a negative result can miss risks outside the test’s scope. The FDA describes a haemochromatosis genetic health-risk report that checks C282Y and H63D, but it does not measure a person’s overall likelihood of iron overload. A positive result is not a treatment instruction. Clinical review may be needed to establish what the finding means and whether further testing is appropriate. Keep the complete report rather than relying only on a coloured risk label or a summary generated by another website. ^[21]

Symptoms: useful clues, not a self-test

Some people have no symptoms when haemochromatosis is identified. Others describe persistent tiredness, weakness, joint pain, abdominal discomfort or changes in sexual function. Symptoms may develop gradually and have many other possible explanations. Later complications can involve the liver, heart, pancreas and joints. Skin darkening is sometimes described, but appearance is not a dependable way to identify the condition or judge its severity. ^[6]

Arrange a medical review for persistent or concerning symptoms, and mention a diagnosed parent or sibling even if you feel well. A symptom checklist cannot confirm haemochromatosis. Equally, feeling well does not answer every question raised by a family diagnosis or abnormal testing. A clinician can decide what assessment is appropriate to the combination of information available. ^[6]

Ferritin and transferrin saturation answer different questions

An iron assessment commonly includes serum ferritin and transferrin saturation, often shortened to TSAT. Ferritin is used as an indirect indicator of stored iron. TSAT describes how much of the blood’s iron-binding capacity is occupied; it is calculated using blood iron and iron-binding measurements. The results provide complementary information. A single serum iron value, without the rest of the assessment, is not a complete account of iron status. ^[7]

An unexpected result may need repeating. Laboratories and clinical pathways differ in their preparation instructions, including whether fasting is requested. Follow the instructions from the service arranging your test rather than changing food or medicine routines from an internet example. The clinician interprets the pattern together with medical history and possible alternative causes. ^[7]

An iron panel can contain several related names. Serum iron measures iron circulating in the blood. A transferrin test measures the transport protein itself. Total iron-binding capacity, or TIBC, assesses the blood’s capacity to bind iron. TSAT expresses occupancy of that capacity, whereas ferritin gives information about storage. These measurements are related, but their numbers are not interchangeable. Serum iron can vary during the day, which is one reason that a clinician reviews the whole pattern and the circumstances of collection instead of treating an isolated value as a precise inventory of body iron. ^[22]

A full blood count, haemoglobin and haematocrit may be requested alongside iron tests. They assess blood-cell features rather than directly measuring tissue iron. Their inclusion is useful when anaemia or the safety of blood removal is being considered. Seeing both a blood count and an iron panel on a request form therefore does not mean the same question has been ordered twice. ^[22]

Why a high ferritin result needs context

Ferritin can rise with inflammation, infection, alcohol-related problems, metabolic conditions, kidney disease and liver injury, as well as with iron overload. A high result therefore does not automatically mean that excess iron is causing damage. Assessment may include repeat ferritin and TSAT, a blood count, kidney and liver tests, and a review of relevant medical history. The purpose is to identify the explanation, not merely attach a name to an abnormal number. ^[8]

The context may include recent illness, alcohol intake, transfusions, known liver disease and metabolic health. Tell the clinician about these without deciding in advance which explanation is correct. More than one issue may require attention, and discovering another cause of high ferritin does not make the original blood test unimportant. ^[8]

Ferritin is a protein that binds and stores iron, and the blood test measures that protein in a sample. It is useful at both ends of the iron balance: low results can support investigation for iron deficiency, while high results need interpretation for overload and other causes. Inflammation after illness or surgery can influence ferritin, and some medicines can alter the result. This is why “high” and “low” are starting descriptions rather than complete diagnoses. A sample taken for a ferritin test is an investigation; it should not be confused with a prescribed course of therapeutic blood removal. ^[23]

Metabolic health is particularly relevant when ferritin is elevated. Fatty liver and metabolic conditions can raise ferritin without the same pattern of iron loading as hereditary haemochromatosis. Liver-cell injury can also release ferritin into the blood. Persistently unexplained abnormalities deserve evaluation, even when a common HFE result is absent. Removing blood simply because ferritin is high can expose someone without true overload to iron deficiency and procedure-related problems while leaving the actual cause untreated. The clinical question is what explains the abnormality and which intervention addresses that explanation. ^[24]

How clinicians build a diagnosis

Diagnosis combines the iron pattern, clinical history and appropriate genetic testing. In the typical HFE C282Y homozygous setting, compatible blood findings can establish the diagnosis without a liver biopsy. With raised TSAT and ferritin but other HFE results, EASL guidance requires evidence of liver iron overload on MRI or biopsy before diagnosing haemochromatosis. This protects against treating every abnormal genetic or blood finding as the same disease. ^[9]

An H63D result, including a C282Y/H63D combination, should not automatically be treated as proof of clinically important haemochromatosis. Its interpretation depends on the person’s iron loading and other contributors. Specialist investigation for less common causes may be appropriate when the findings are unusual. A negative common HFE test does not resolve every possible iron disorder. ^[9]

The scope of a genetic test matters. A targeted HFE test examines specified variants; broader testing looks beyond those common findings. Expanding a panel is not automatically the next step for every abnormal ferritin result. Genetic diagnostic guidance places testing within the clinical assessment and emphasises accurate interpretation. A clinician may first need to clarify whether iron overload is present and whether another condition explains it. ^[20]

Checking whether organs have been affected

Assessing iron accumulation and assessing organ injury are related but different tasks. A liver MRI can estimate iron concentration using a suitable technique. Fibrosis means liver scarring; its assessment may involve blood-based measures, elastography and, in selected cases, biopsy. Elastography examines tissue stiffness rather than directly measuring iron. The specialist chooses and interprets these tests in context instead of assuming that one scan answers every question. ^[10]

The assessment may also consider diabetes, heart disease, joint problems and hormone-related symptoms when the history or examination suggests them. Liver fibrosis staging is especially important because it influences longer-term care. Additional liver risks, including metabolic disease and alcohol exposure, can affect that evaluation. Not everyone with haemochromatosis needs the same set of cardiac, endocrine or liver investigations. ^[10]

Iron can affect several organs because it is carried through the body and stored in tissues. Significant accumulation in the pancreas can contribute to diabetes, while heart involvement can affect rhythm or pumping function. Liver injury can become serious over time. These are possible complications, not a checklist of inevitable outcomes for everyone receiving a diagnosis. ^[3]

A quantitative iron MRI uses the way iron changes magnetic-resonance signals to estimate liver iron concentration. It is more specific than simply looking at the shape of the liver on an ordinary image. Validated techniques and specialist interpretation matter because factors such as liver fat and technical differences can affect measurement. Radiology consensus guidance describes methods designed to account for such influences. The report may name a technique as well as give a concentration estimate; that measurement belongs in the wider clinical picture and cannot be translated directly into a blood-removal schedule by the patient. ^[25]

Ultrasound elastography uses vibrations and sound waves to assess how stiff liver tissue is. Magnetic resonance elastography uses a different imaging approach to evaluate stiffness. Both can help investigate scarring without taking a tissue sample, but stiffness results have limitations: inflammation, obesity and other circumstances can affect accuracy. A fibrosis score is therefore interpreted with the cause of liver disease and other findings. It is possible for a report to contain information about stiffness or fat without providing the specialised iron measurement needed for a different clinical question. ^[26]

A liver biopsy removes a small piece of tissue for examination by a pathologist. It can help identify a cause of liver disease or establish the extent of damage when blood tests and imaging leave an important question unresolved. It is not an automatic requirement for everyone with haemochromatosis. Because biopsy is invasive and can cause bleeding or other complications, the team reviews its expected benefit, clotting status, medicines and the safest method. If it is proposed, the patient receives individual preparation and aftercare instructions, including any clinician-directed changes to medicines. ^[27]

Treatment is a supervised plan to reduce excess iron

Therapeutic phlebotomy, also called venesection, is the usual treatment for suitable patients with haemochromatosis and iron overload. Removing blood prompts the body to use stored iron to replace red cells. Treatment often has an initial iron-reduction phase followed by maintenance. The clinician individualises the plan using the degree of overload, other illnesses, age, treatment tolerance and laboratory results. ^[11]

Ferritin helps guide treatment, while haemoglobin checks help protect against excessive blood removal and anaemia. Treatment may need adjusting or pausing during illness or if it is poorly tolerated. More intensive treatment is not automatically better. Amounts, intervals and targets belong in a prescribed plan, with trained staff carrying out the procedure and reviewing its safety. ^[11]

Erythrocytapheresis is a specialised procedure that removes red blood cells while returning other blood components. It can be considered in selected circumstances, but equipment, expertise and individual suitability limit its use. Chelation and other alternatives likewise require clinicians experienced in iron disorders. The existence of another technique does not make it interchangeable with a prescribed venesection plan. Choice depends on the medical problem, the expected benefit and the ability to carry treatment out safely. ^[19]

Preparing for treatment and discussing alternatives

During or after phlebotomy, some people experience dizziness, faintness, nausea or bruising at the needle site. Report these effects to the staff. Ordinary blood donation does not replace medical monitoring. Donation can only form part of care when the treating team and donor service confirm that it is appropriate and maintain the necessary clinical oversight. Do not arrange extra donations to lower a laboratory number yourself. ^[12]

If blood removal is unsuitable, a specialist may consider another approach, such as iron-chelating medicine. Chelation binds iron so the body can eliminate it, but it is not a routine substitute for phlebotomy in hereditary haemochromatosis. The reason blood removal is unsuitable and the risks of an alternative need individual assessment. ^[12]

Donor eligibility is a separate decision from whether someone needs therapeutic treatment. For example, Australian Red Cross Lifeblood requires a doctor’s referral and medical eligibility assessment for its haemochromatosis therapeutic programme. A person with high ferritin from another cause must first have the cause investigated and significant underlying problems addressed. This is a local service example, not a universal rule for every country. A donation service’s acceptance process cannot determine the full medical plan, and being declined as a donor does not mean that clinically necessary care should stop. ^[28]

What treatment can and cannot promise

Reducing excess iron can lower the risk of further complications, and some symptoms or organ abnormalities may improve. Established problems do not all respond in the same way. Joint pain, diabetes and sexual or hormone-related difficulties may persist and need their own care. Improvement in an iron measurement cannot be used as a promise that every symptom or existing injury will disappear. ^[13]

The outlook depends in part on how much injury was present when treatment began. Earlier recognition offers an opportunity to address overload before severe damage develops. Treatment manages the consequences of the inherited tendency; it does not remove that genetic tendency. Follow-up therefore remains important even when the initial treatment has achieved its intended result. ^[13]

Haemochromatosis-related arthritis can affect the hands and fingers, as well as larger joints. Pain and stiffness may resemble other forms of arthritis. Joint damage may remain after iron levels improve, so ongoing symptoms are not a reliable reason to assume that more blood removal will solve the problem. Assessment may include examination and imaging to distinguish the joint condition and guide a separate management plan. ^[29]

Support for affected joints can include individually suitable exercise, physiotherapy, occupational-therapy advice and discussion of pain relief. Some people with substantial damage need specialist orthopaedic assessment. Medicines and activity advice should take other health problems into account. The aim is to protect function and manage symptoms while the iron disorder continues to receive appropriate care. ^[29]

Food, supplements and alcohol: keep changes proportionate

Most people do not need an extreme low-iron diet. NIDDK advises balanced eating and explains that dietary changes have a relatively small effect compared with iron-removal treatment. Avoid iron-containing supplements and vitamin C supplements unless your clinician specifically advises them. Discuss all supplements and herbal products with the team. Avoid raw or undercooked shellfish because of the risk of serious infection. ^[14]

Alcohol advice depends on liver health and should be discussed explicitly. NIDDK recommends avoiding alcohol completely with cirrhosis; without cirrhosis, the clinician may advise limiting intake. Food changes cannot replace indicated treatment. Ask for individual dietary advice if another condition, poor appetite or an existing restrictive diet makes balanced eating difficult. ^[14]

Foods contain different forms of iron. Haem iron occurs in animal foods, while non-haem iron occurs in plant foods and many fortified products; the body absorbs these forms differently. General nutrition guidance explains these differences, but it does not provide a personal treatment prescription for iron overload. The presence of iron on a food label is not, by itself, a complete eating plan. ^[2]

The warning about raw seafood is about infection as well as nutrition. Vibrio bacteria naturally occur in coastal waters and can be present in oysters and other seafood. People with liver disease are particularly vulnerable to serious illness. Cook seafood properly, keep raw seafood and its juices away from ready-to-eat food, and wash hands after handling it. Coastal water and raw seafood can also expose open wounds to infection. CDC advises keeping such wounds out of salt or brackish water when possible and protecting them from contact. These precautions are especially relevant when liver disease accompanies iron overload. ^[30]

Talking with relatives about a diagnosis

Adult relatives of someone with hereditary haemochromatosis should discuss testing with a healthcare professional. That conversation is useful even when relatives feel well. The clinician can establish what has been diagnosed in the family and decide what assessment fits the relative’s circumstances. Family testing is a clinical discussion, not a reason to diagnose someone from a shared surname, appearance or symptom. ^[15]

Genetic counselling can help a family understand what a confirmed result does and does not establish, how inheritance applies to the particular condition, and the implications of testing. It can also support decisions about whether to be tested and how to discuss results. The process considers medical and family history together with personal concerns; it is more than reading a variant name from a report. ^[32]

The priority in common adult HFE-related haemochromatosis is usually adult close relatives, particularly siblings, with adult children also considered. The family’s confirmed result helps direct the conversation. Routine predictive testing of young children for the adult-onset form is generally not useful; an individual concern belongs with a clinician or genetics service. Juvenile haemochromatosis is a distinct, rare condition with a different genetic basis and earlier presentation. A family history of common adult HFE-related disease does not mean that a child is expected to develop the juvenile form. Symptoms in a child still deserve assessment on their own merits. ^[31]

Long-term care includes more than the iron result

For people who already have cirrhosis, liver-cancer surveillance remains important after iron has been reduced. AASLD guidance specifically recognises that treating overload does not remove that surveillance need. The liver team determines the appropriate programme. Advanced fibrosis also requires specialist consideration of ongoing risk. A reassuring iron result should not be used on its own to cancel liver follow-up that was arranged for established scarring. ^[16]

The reason for continuing surveillance is the risk associated with established liver disease, rather than whether a person feels ill on the day of a scan. Bringing iron into the intended range and checking for complications of cirrhosis address different concerns. Both can remain part of care, with the specialist explaining which follow-up applies to the individual. ^[16]

Care also includes reducing avoidable additional liver harm. Discuss recommended vaccinations, including hepatitis A and B where appropriate, with your clinician. CDC includes vaccination and infection prevention in haemochromatosis care. These measures accompany the iron plan rather than replacing it, and the recommendations should be checked against your vaccination history and other medical circumstances. ^[15]

Cirrhosis changes the structure of the liver as scar tissue replaces healthy tissue. It can interfere with normal liver function and blood flow. Complications can include fluid accumulation in the abdomen, bleeding from enlarged veins and episodes of confusion related to impaired liver function. These complications require their own clinical management. They are not inevitable consequences of a haemochromatosis diagnosis, but they explain why established advanced liver disease needs a broader care plan than iron reduction alone. ^[33]

Living with the uncertainty and workload of care

Patient support can include emotional as well as practical help. Haemochromatosis UK provides information about mental health and finding support. Such resources can help you prepare a conversation, but they do not establish the cause of a symptom or replace an individual mental-health assessment. If worry, low mood or the burden of care is becoming difficult, raise it with a healthcare professional. ^[17]

Preparing one clear plan for your next review

Bring your questions together on one page. Put the immediate concern first: understanding a result, getting an explanation for a persistent symptom, or resolving a difficulty with the agreed appointments. Keep the original reports available rather than copying fragments into a message. In your own notes, separate what the clinician has confirmed from questions that remain open. This makes the next discussion easier to follow without asking you to make a diagnosis.

Explain practical barriers concretely, such as travel costs, shift work or caring responsibilities. Ask which arrangements the service can offer and how to contact it if the booking system does not match the plan. Before the appointment ends, repeat back the next steps, who is responsible for each one and how you will receive outstanding results. Keep one current version of those arrangements so that you and anyone helping you are working from the same information.

When telling family or people at work, choose the amount of personal detail you want to share. A brief explanation of an appointment or a request for a family discussion may be enough. You can ask for a written summary from the clinical team and decide who should receive it. Practical support should make care easier to manage while leaving you in control of your own information.